How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/kras-g12c-mutated-locally-advanced-or-metastatic-non-small-cell-lung-cancer.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (disease) competitive landscape: 2 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

2 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	Line of therapy	First approval
Krazati	ADAGRASIB	Bristol-Myers Squibb		GTPase KRas		2022-01-01
Lumakras	SOTORASIB	Amgen		GTPase KRas		2021-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Amgen · 1 drug in KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer
Bristol-Myers Squibb · 1 drug in KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer:

Cite this brief

Drug Landscape (2026). KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/kras-g12c-mutated-locally-advanced-or-metastatic-non-small-cell-lung-cancer. Accessed 2026-06-10.

KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing